Document ID: chunk:federal_register_of_legislation:F2022C00585:reg:7
Version: federal_register_of_legislation:F2022C00585
Segment Type: reg
Provision Reference: reg 7
Character Range: 3370–4961

7               Kind of injury, disease or death to which this Statement of Principles relates
(1)          This Statement of Principles is about immune thrombocytopaenia and death from immune thrombocytopaenia.
Meaning of immune thrombocytopaenia
(2)          For the purposes of this Statement of Principles, immune thrombocytopaenia means:
(a)          an autoimmune disorder characterised by an isolated thrombocytopaenia, and a peripheral platelet count of less than 100 000 per microlitre, together with either:
(i)            the presence of bleeding symptoms; or
(ii)         the need for treatment to increase the platelet count; and
                Note: Bleeding symptoms can include bruising (purpura), mucocutaneous bleeding (petechiae), retinal haemorrhage, intracranial haemorrhage, nose bleeds (epistaxis), bleeding from the bowels (melaena) and vaginal bleeding (menorrhagia).
(b)          excludes pseudothrombocytopaenia, thrombocytopaenia that is caused by non-immunological mechanisms, allergic and other non-thrombocytopaenic purpura, purpura caused by qualitative platelet defects, thrombotic thrombocytopaenic purpura, Evan's syndrome, pancytopaenia, and thrombocytopaenia occurring in the presence of abnormal red or white blood cells.
Death from immune thrombocytopaenia
(3)          For the purposes of this Statement of Principles, immune thrombocytopaenia, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's immune thrombocytopaenia.
Note: terminal event is defined in the Schedule 1 – Dictionary.